Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | GLS | O94925 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.32 |
| ▸ | KDM6B | O15054 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446383 | 0.94 | NR1H4 (0.38) | MAPTMAPK14NR1H4GLSALDH1A1 | |
| SCHEMBL12391991 | 0.88 | DGAT1 (0.39) | MAPTNR1H4GLSALDH1A1LMNA | |
| SCHEMBL26414505 | 0.86 | ALDH1A1 (0.34) | MAPTNR1H4GLSALDH1A1LMNA | |
| SCHEMBL13350010 | 0.84 | MAPT (0.45) | MAPTMAPK14JAK3GLSIRAK4 | |
| SCHEMBL12392027 | 0.83 | MGLL (0.49) | MAPTMAPK14NR1H4ALDH1A1LMNA | |
| SCHEMBL12391987 | 0.83 | MAPT (0.40) | MAPTMAPK14JAK3GLSALDH1A1 | |
| SCHEMBL12451999 | 0.82 | MAPT (0.43) | MAPTMAPK14GLSIRAK4ALDH1A1 | |
| SCHEMBL24841212 | 0.82 | MAPT (0.46) | MAPTMAPK14GLSALDH1A1LMNA | |
| SCHEMBL12286925 | 0.81 | SCD (0.46) | MAPTMAPK14JAK3GLSIRAK4 | |
| SCHEMBL15223683 | 0.81 | GLS (0.47) | MAPTGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2017-11-23 | — | — | US | disclosed |
| US-9815784-B2 | CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-8889868-B2 | CC-1065 analogs and their conjugates | SYNTARGA BV (NL) | 2014-11-18 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333567-A1 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MAPT 4526/4885MAPK14 2813/4885JAK3 4659/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | MAPT 4626/4885MAPK14 2612/4885JAK3 4440/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | MAPT 4526/4885MAPK14 2813/4885JAK3 4659/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | MAPT 4526/4885MAPK14 2813/4885JAK3 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.